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Abstract Mounting evidence suggests that helminth infections protect against autoimmune
diseases. As helminths cause chronic IgE-mediated activation of basophils and mast cells we
hypothesized that continuous activation of these cells could prevent diabetes onset in nonobese
diabetic (NOD) mice in the absence of infection. Anti-FcεR1 activated basophils and mast cells
and resulted in the release of IL-4 and histamine into the bloodstream. Anti-FcεR1-treated NOD
mice showed a type 2 shift in insulin-specific antibody production and exhibited significant delays
in diabetes onset. IL-4 responses played a partial role as the protective effect of anti-FcεR1
therapy was diminished in IL-4-deficient NOD mice. In contrast, histamine signaling was not
required as anti-FcεR1-mediated protection was not reduced in mice treated with histamine
receptor blockers. These results demonstrate that anti-FcεR1 therapy delays diabetes onset in
NOD mice and suggest that chronic basophil and mast cell activation may represent a new avenue
of therapy for Th1-associated autoimmune diseases.
Published by Elsevier Inc.
1. Introduction
The prevalence of Type 1 diabetes and other autoimmune
diseases has increased sharply over the past few decades
[1–6]. While genetic factors play a role in susceptibility to
Type 1 diabetes, it is probable that the dramatic worldwide
increase in the prevalence of Type 1 diabetes is due to
changes in environmental factors.
One environmental change thatmay be responsible for the
recent increase in autoimmune diseases is the loss of chronic
parasitic worm infections in developed countries. Multiple
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studies have found that individuals with chronic parasitic
worm infections have lower rates of autoimmune diseases
than others living in the same environment (reviewed in [7]).
Experimentally, parasitic worms have been shown to protect
against Type 1 diabetes and other autoimmune diseases in
several animal models [8–10], and in humans oral adminis-
tration of porcine whipworm eggs results in protection
against inflammatory bowel disease [11].
Until recently, most people had lifelong infections with
parasitic worms. As helminths have been identified in
neolithic and pre-Columbian mummies [12,13], it is likely
that the human immune system evolved in the setting of
chronic infection with these parasites [14]. Consequently,
many scientists argue that the loss of parasitic worm
infections is partially responsible for the increased preva-
lence of autoimmune and allergic diseases in developed
countries — the notion being that now, in the absence of the
immunomodulatory responses triggered by helminths, our
immune systems have become hyperresponsive [9,14,15].
In this study, we sought to determine whether recapitu-
lation of the IgE-mediated immune responses observed in
chronic helminth infections can protect against Type 1
Figure 1 Anti-FcεR1 activates basophils and mast cells in vitro. (A) May-Grünwald staining of peritoneal mast cells after enrichment by
density centrifugation. (B) Histamine release from mast cells in response to increasing concentrations of anti-FcεR1. (C) Representative
dot plots of intracellular IL-4 staining of basophils after incubationwithmedia or anti-FcεR1. Initial gating of lymphocytes and lower half of
granulocyte region in FSC/SSC plot (left panel). Basophils identified as CD4−B220−IgE+ (middle panel). IL-4 staining of basophils after
incubationwithmedia (upper right panel) or anti-FcεR1 (lower right panel). (D) Percentages of basophils that stain positively for IL-4 after
incubation with media or anti-FcεR1. (E) IL-4 release from whole blood after incubation with anti-FcεR1. Error bars denote SEM. Results
from 4 to 6 animals per group are shown. Each experiment was independently performed twice. Statistical significance assessed per one-
tailed paired T-test.
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diabetes in the absence of actual infection. Unlike most
bacterial or viral pathogens, helminth infections induce the
production of specific IgE. This IgE binds to basophils and
mast cells through FcεR1, the high affinity IgE receptor.
Helminth specific antigens can then activate basophils and
mast cells by cross-linking IgE molecules and aggregating
FcεR1s. As helminths are large organisms that release
substantial amounts of antigen, and as these infections last
for years, helminth infections likely induce a state of chronic
basophil and mast cell activation. Indeed, recent time course
studies in our lab demonstrate that both chronic basophil
[16] and chronic mast cell activation (E. Mueller and E. Mitre,
unpublished data) occur during infection of mice with the
filarial nematode Litomosoides sigmodontis.
There are two mechanistic rationales for postulating that
chronic activation of basophils and mast cells may protect
against Th1-driven autoimmune disease. First, factors
released by basophils and mast cells may have direct
immunomodulatory properties that are protective against
Th1-mediated autoimmune diseases. Basophils, for example,
release large quantities of IL-4 when activated and have
been shown to do so in response to parasite antigen in filaria-
infected patients [17] as well as in animal models of helminth
infection [16,18–20]. As destruction of beta-islet cells in
Type 1 diabetes is driven by IFNγ release from Th1 cells, and
as IL-4 counterregulates Th1 responses and has been shown
to improve Th1-driven autoimmune diseases [21,22], it is
possible that chronic basophil activation could protect
against Type 1 diabetes by release of IL-4. Similarly,
histamine, which is released from both basophils and mast
cells, has been shown in vitro to suppress Th1 responses by
signaling through the H2 receptor on lymphocytes [23].
Alternatively, chronic activation of basophils and mast cells
could induce negative feedback pathways that tamp down
ongoing autoimmune responses. Interestingly, there is
substantial evidence that chronic immunotherapy, in which
patients with IgE-mediated allergies are given weekly
injections of allergen, augments immune regulatory net-
works such as the suppressive cytokine IL-10 and natural
T-regulatory cells [24,25].
To test the hypothesis that chronic activation of basophils
and mast cells can protect against a Th1-driven autoimmune
disease, we studied the effects repeated anti-FcεR1 antibody
injections have on the development of Type 1 diabetes in the
NOD mouse model. Our studies demonstrate that anti-FcεR1
therapy activates basophils and mast cells, induces IL-4 and
histamine release in vivo, and delays Type 1 diabetes onset in
the NOD mouse. Studies using IL-4-deficient NOD mice and
therapeutic histamine blockade reveal that IL-4, but not
histamine signaling through H1 or H2 receptors, plays a
partial role in the protective effects of anti-FcεR1 therapy.
2. Materials and methods
2.1. Mice
Female NOD and IL-4-deficient NOD.129P2(B6)-Il4tm1Cgn/DvsJ
mice (The Jackson Laboratory) were maintained at the
Uniformed Services University (USU) animal facility with free
access to food and water. All experiments were performed
under protocols approved by the USU Institutional Animal Care
and Use Committee.
2.2. Assessment of diabetes
Glucose levels of mice were determined from blood taken by
orbital bleeds every other week using a standard blood
Figure 2 Effects of anti-FcεR1 injections in vivo. Percentages of circulating white blood cells that are basophils (A) and percentages
of peritoneal cells that are mast cells (B) in mice one day after intraperitoneal injection of 50 μg of isotype control antibody or anti-
FcεR1. (C) Plasma IL-4 concentration as measured by in vivo cytokine capture assay one day after anti-FcεR1 or isotype antibody
injection. (D) Histamine concentration in plasma 30 min after anti-FcεR1 or isotype antibody injection. Statistical significance
between groups was assessed by the Mann–Whitney test. Joined data from two independent experiments is shown with 5 animals per
group and experiment.
207Anti-FcεR1 treatment delays diabetes onset
glucose meter (Accu-Check Advantage, Roche Diagnostics
GmbH). Mice with glucose levels greater than 230 mg/dl in
two consecutive measurements were considered diabetic.
2.3. Treatment with anti-FcεR1
Beginning at 6-weeks of age mice were given weekly i.p.
injections of 50 μg Armenian hamster anti-mouse FcεR1
(MAR-1, eBioscience) or control Armenian hamster IgG
(Isotype Control, Functional Grade Purified, eBioscience)
throughout the experiment.
Subsets of animals were euthanized at 16 weeks of age,
one day after the last anti-FcεR1 or IgG injection, to assess
pancreas inflammation, splenic and pancreatic lymph node
cytokine production, cell subtypes, as well as insulin-specific
IgG1 and IgG2c levels.
Different shorter anti-FcεR1 treatment regimens were
tested starting at 6-weeks of age. Those regimens included
weekly i.p. injections of 50 μg anti-FcεR1 or control IgG for
four weeks and i.p. injections of 25 and 50 μg anti-FcεR1 or
control IgG twice a week for four weeks.
2.4. Assessment of pancreas inflammation
At 16 weeks of age, pancreases were isolated and fixed in 10%
formalin (Protocol, Fisher Scientific Company). Hematoxylin–
eosin stained slices were assessed for inflammation by a
pathologist blinded to the intervention group. Total numbers
Figure 3 Treatment with anti-FcεR1 delays the onset of diabetes. (A) Mean blood glucose levels and (B) percentages of NOD mice
with diabetes during treatment with weekly injections of 50 μg anti-FcεR1 (n=9) or IgG control antibody (n=17). (C) Mean total
numbers of pancreatic islets from anti-FcεR1 or isotype treated mice at 16 weeks of age (9–10 animals per group). Pancreatic islets
were classified as non-infiltrated, periinsulitis, and intrainsulitis with less than or more than 50% infiltrated lymphocytes. (D) Blood
glucose levels and (E) percentages of diabetic mice that received either weekly injections of 50 μg anti-FcεR1 for four weeks or
injections of 25 or 50 μg anti-FcεR1 twice a week for four weeks (n=8 per group) or isotype controls (n=11). Error bars denote SEM.
Statistical significance between groups was assessed by the Mann–Whitney test (*b0.05). Shown are the combined results from 2 to 3
independent experiments.
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Figure 4 Cytokine and antibody response after 10 weeks of anti-FcεR1/isotype treatment at 16 weeks of age. (A) IFNγ, (B) IL-4, and
(C) IL-5 cytokine production from spleen cells and (D) IFNγ and (E) IL-5 cytokine production from pancreatic lymph node cells in
response to anti-CD3/anti-CD28. (F) Frequency of splenic CD4+IFNγ+ and (G) CD8+IFNγ+, as well as (H) CD4+IL-4+ and (I) CD4+IL-17+ T
cells in response to anti-CD3/anti-CD28. (J) Plasma levels of insulin-specific IgG1 and (K) IgG2c. Statistical significance between
groups was assessed by the Mann–Whitney test. Shown are the results from two independent experiments with a total of 9–10 animals
per group.
209Anti-FcεR1 treatment delays diabetes onset
of islets of three longitudinal sections 400 μm apart of each
pancreas were assessed. The severity of insulitis was scored as
non-infiltrated, periinsulitis (lymphocytes at the periphery of
islets), or intrainsulitis (lymphocyte infiltration into the interior
of the islets lesser or greater than 50%).
2.5. Spleen and pancreatic lymph node cell culture
At 16 weeks of age, animals that were treated for 10 weeks
with either anti-FcεR1 or control IgG were euthanized and
spleen and pancreatic lymph nodes were isolated. Spleen and
pancreatic lymph node cells were prepared and cultured as
previously reported [8]. In brief, single cell suspensions were
obtained, red blood lysis was performed for spleen cells (ACK
Lysing Buffer, Quality Biological, Inc.), and cellswereplatedat
a concentration of 2×106 cells/ml in enriched media (Iscove's
Dulbecco modified medium (Mediatech) including 10% fetal
calf serum (Valley Biomedical), 1% L-glutamine (Mediatech),
1% insulin–transferrin–selenium medium (Invitrogen Inc.) and
80 μg/ml gentamicin (Quality Biological, Inc.)), stimulated
with 5 μg/ml anti-CD3 and 2 μg/ml anti-CD28 (eBioscience),
and cultured at 37 °C, 5% CO2.
2.6. Flow cytometric analysis of regulatory cell types
and intracellular cytokine production by T cells
Spleen and pancreatic lymph node cells were cultured as
described above and prepared for flow analysis as previously
reported [8]. In brief, after two hours of incubation, BD
GolgiStopwas added (BDBiosciences) and cells were incubated
for an additional four hours. Collected cells were fixed and
permeabilized (eBioscience) overnight. For analysis cells were
washed once with phosphate-buffered saline (PBS)/1%BSA
(bovine serum albumin, Sigma), followed by a blocking step
with PBS/1%BSA. Cells were washed with 1× permeabilization
buffer (eBioscience) and stained for five- or four-color-flow
Figure 5 Frequency of regulatory cell types and IL-10 production after 10 weeks of anti-FcεR1/isotype treatment at 16 weeks of age.
(A) Frequency of splenic and (B) pancreatic lymph node CD4+CD25+FoxP3+ regulatory T cells in response to anti-CD3/anti-CD28.
(C) Frequency of spontaneous splenic CD8+FoxP3+ regulatory T cells, (D) anti-CD3/anti-CD28 stimulated IL-10+ B-cells, and (E) B220+
CD5+CD1d+ regulatory B-cells. (F) IL-10 release from spleen as well as (G) pancreatic lymph node cells in response to anti-CD3/anti-
CD28. Statistical significance between groups was assessed by the Mann–Whitney test (spleen: 9–10 animals per group, pancreatic
lymph node: 6 animals per group, CD8+ and B-regulatory cells: 4 animals per group). Shown are the results from two independent
experiments.
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using CD4 PerCP, IL-4 APC (BD Biosciences), CD8a Pacific Blue,
gamma interferon (IFN-γ) FITC, and IL-17 PE (eBioscience) or
CD4 PerCP (BD Biosciences), FoxP3 FITC, CD25 APC-Alexa Fluor
750, and IL-10 PE (eBioscience). For identification of regula-
tory CD8 T-cells and regulatory B cells, fixed, cryopreserved
(PBS/10% DMSO) spleen cells were washed once, blocked with
CD16/CD32 (BD Biosciences) and stained with CD4 Qdot 605
(Invitrogen), CD8 PE Cy5, FoxP3 FITC, (all eBioscience) or B220
PerCP, CD1d FITC, CD5 APC (all BD Bioscience), and IL-10 PE
(eBioscience). Flow cytometry was performed using a BD LSRII
system and subsequently analyzed with FACSDiva 6.1 software
(BD Biosciences).
2.7. Measurement of cytokines and antibodies by
ELISA
Cytokine enzyme-linked immunosorbent assays (ELISAs) were
performed from spleen and pancreatic lymph node cell
cultures. Culture supernatants from cells that were cultured
Figure 7 Deficiency of IL-4 reduces anti-FcεR1 mediated protective effect. (A) Blood glucose levels and (B) percentages of mice
with diabetes in IL-4 deficient NOD mice that were injected weekly with 50 μg anti-FcεR1 (n=11) or an IgG control antibody (n=15).
Error bars denote SEM. Statistical significance between groups was assessed by the Mann–Whitney test. Shown are the results from
four independent experiments.
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Figure 6 Histamine receptor blockage does not decrease anti-FcεR1 mediated delay of diabetes onset. (A) Stomach pH from animals
that were treated for 2 weeks with the histamine receptor blockers cimetidine and fexofenadine (5 animals per group).
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ear) and IgG control (right ear). The bottom mouse was treated with fexofenadine, a histamine receptor 1 blocker, whereas the top
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as described above and stimulated with anti-CD3 and anti-
CD28 were collected after 72 h of incubation. IFN-γ, IL-4,
IL-5, and IL-10 were quantified according to the manufac-
turer's instructions (BD Biosciences).
Plasmaderived insulin-specific IgG1and IgG2cwere analyzed
by sandwich ELISA as previously described [8]. All samples were
analyzed as duplicates at the same time on the same plate to
allow accurate comparison between groups by OD.
2.8. Flow cytometric analysis of basophils and mast
cells
Frequency of basophils in the peripheral blood and perito-
neal mast cells was measured by flow cytometry one day
after a single injection of 50 μg anti-FcεR1 or control IgG in
8-week old female NOD mice.
Basophil flow was performed as previously described [26].
In brief, 100 μl of blood obtained by orbital bleeding was
diluted with 100 μl of RPMI media (RPMI-1640, Mediatech),
red blood cells were lysed and cells were fixed (whole blood
lysing reagent kit, Beckman Coulter, Inc.). After two washing
steps with 1× PBS, cells were blocked overnight with PBS/1%
BSA. Cells were washed and stained with IgE FITC (BD
Biosciences), CD4 PerCP (BD Biosciences) and B220 PerCP (BD
Biosciences). During flow cytometric analysis, basophils were
identified as CD4−/B220−/IgE+ cells.
Mast cells were obtained by a peritoneal wash with 1×
HBSS (Gibco) and fixed after red blood cell lysis (whole blood
lysing reagent kit, Beckman Coulter). Cells were washed
once and blocked overnight in PBS/1% BSA. 1×106 peritoneal
cells were stained for flow with IgE FITC (BD Biosciences) and
cKit APC (BD Biosciences). During flow cytometric analysis,
mast cells were identified as IgE+/cKit+ cells.
2.9. Detection of histamine from in vitro stimulated
purified mast cells
For in vitro activation of mast cells, peritoneal mast cells
were purified using a 70% percoll gradient. 2000 mast cells
were cultured in 250 μl histamine release buffer (Immuno-
tech S.A.S.) and stimulated with isotype (10 μg/ml) or anti-
FcεR1 (0.4, 1.6, 6.25, 25, 100 μg/ml) for 30 min. Cells were
acylated and histamine ELISA performed according to the
manufacturer's instructions (Immunotech S.A.S.).
2.10. Intracellular IL-4 detection of in vitro stimulated
basophils
For intracellular IL-4 detection of basophils, 100 μl of
peripheral blood from NOD mice was cultured with GolgiStop
(BD Bioscience) and either media, 10 μg/ml isotype control,
10 or 25 μg/ml anti-FcεR1 (MAR-1) for a total of 6 h at 37 °C.
Following red blood lysis and fixation (performed as
mentioned above) cells were stained in a two step procedure
for flow. Cells were stained for the surface markers IgE FITC,
CD4 PerCP, and B220, followed by permeabilization (per-
meabilization buffer, BD Bioscience) and staining with IL-4
APC (BD Bioscience).
As basophils are the only circulating cells inmice that express
FcεR1, IL-4 release fromwholebloodwasmeasuredafter in vitro
stimulation of 100 μl of peripheral blood from NOD mice
cultured with 10 μg/ml anti-FcεR1 antibody, 10 μg/ml IgG
isotype control, or media for 6 h at 37 °C. Plasma was obtained
by centrifugation and stored at −20 °C until the IL-4 ELISA was
performed as per themanufacturer's instructions (eBioscience).
2.11. In vivo cytokine capture assay to detect IL-4
release after anti-FcεR1 injection
10 μg biotinylated IL-4 antibody (BD Bioscience) was injected
i.p. into 11-week old NOD mice. The following day mice were
injected i.p. with 50 μg anti-FcεR1 or control IgG and one day
later blood was collected by orbital bleed. Concentration of
IL-4 was measured by ELISA according to the manufacturer's
instructions (BD Biosciences).
2.12. Detection of in vivo histamine release after
injection of anti-FcεR1
Mice were i.p. injected with a single dose of 50 μg anti-FcεR1
or control IgG. After 30 min, blood was collected by orbital
bleed. 100 μl of blood was immediately acylated and
histamine ELISA was performed according to the manufac-
turer's instructions (Immunotech S.A.S.).
2.13. Treatment with histamine receptor blockers
Starting at 6-weeks of age, 2.5 mg/ml cimetidine (Sigma), an
H2-receptor blocker, and 0.25 mg/ml fexofenadine HCl
(TEVA Pharmaceuticals USA), an H1-receptor blocker, were
added to the drinking water of NOD mice. The treated
drinking water was freshly prepared every other day
throughout the experiment until 25 weeks of age.
Efficacy of H2-receptor blockage was tested by measuring
the stomach pH 2 days after changing the drinking water in
mice that had been receiving fexofenadine and cimetidine
treatments for 2 weeks. Mice were euthanized and the
stomach pH was measured using pH strips (Micro Essential
Laboratory). In addition, blockage of the histamine-recep-
tors was confirmed in vivo by injecting 10 μg anti-FcεR1
intradermally into one ear and 10 μg control IgG in the other,
followed by i.v. injection of 200 μl toluidine blue (Sigma,
0.5% in PBS) 3 min later. The ears were dissected 10 min later
and vascular permeability was measured at 620 nm by the
optical density (OD) of the blue dye extracted from the ears
after o.n. incubation at 63 °C in Formamide (Sigma).
2.14. Statistics
Statistical analyses were performed with GraphPad Prism
software (GraphPad Software). Differences between paired
groups for in vitro studies were analyzed using one-tailed
paired T-test and differences between two unpaired groups for
in vivo studies were tested for significance with the Mann–
Whitney-U-test. P-valuesb0.05 were considered significant.
All experiments were performed at least twice.
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3. Results
3.1. Anti-FcεR1 antibody activates basophils and
mast cells of NOD mice
To evaluate the effects anti-FcεR1 antibody has on mast cells
in vitro, histamine release from mast cells purified from the
peritoneal cavity of NOD mice was assessed in response to in
vitro incubation with various concentrations of anti-FcεR1.
Density gradient centrifugation of peritoneal cells resulted in
high level enrichment of mast cells (>70% purity for all
samples, Fig. 1A). While incubation of enriched mast cells
with media or isotype antibody resulted in no demonstrable
histamine release above incubation with media alone,
incubation with increasing concentrations of anti-FcεR1
antibody resulted in a classical mast cell activation curve
(Fig. 1B).
To determine whether anti-FcεR1 antibody also activates
basophils in vitro, whole blood samples from NOD mice were
assessed for basophil IL-4 production by intracellular flow
cytometry. Basophils were identified by flow cytometry as
CD4−B220−IgE+ cells (Fig. 1C) as this staining strategy has
been shown to be specific for basophils [26]. Whereas an
average of 18% of basophils stained positively for IL-4 at
baseline, on average 65% were IL-4+ after incubation with
anti-FcεR1 (pb0.0001, Fig. 1D). To confirm that anti-FcεR1
induces IL-4 release from basophils, IL-4 was measured by
ELISA in the supernatants of whole blood samples incubated
with media or anti-FcεR1. As seen in Fig. 1E, anti-FcεR1
caused significant release of IL-4 from whole blood (unsti-
mulated mean IL-4 concentration 32 pg/ml vs. mean
77 pg/ml after anti-FcεR1 stimulation, p=0.03). As basophils
are the only circulating cells in mice that express FcεR1, this
assay confirms that anti-FcεR1 antibody induces IL-4 release
from basophils.
3.2. Anti-FcεR1 injections deplete basophils and
induce massive histamine and IL-4 release in vivo
As both basophils and mast cells express the FcεR1 on their
surface, we tested whether treatment with anti-FcεR1
antibody depletes either peripheral basophils or peritoneal
mast cells by injecting NODmice with 50 μg of anti-FcεR1 and
measuring blood basophil and peritoneal mast cell frequen-
cies by flow cytometry. The frequency of blood cells that
were basophils was significantly reduced one day after
treatment with anti-FcεR1 antibody compared to control
animals (median 0.11%, range 0.05–0.19% vs. 0.40%,
0.19–0.63%, Fig. 2A) whereas the frequency of peritoneal
mast cells was unchanged (median 1.8%, range 0.2–2.5% vs.
2.1%, 0.1–3.2%, Fig. 2B). This finding is consistent with that
of other research groups who have used anti-FcεR1 antibody
to deplete mice of basophils [20,27].
Because aggregation of surface FcεR1 activates basophils
and mast cells, and since our in vitro studies demonstrated
that anti-FcεR1 antibody induces basophils and mast cells to
release IL-4 and histamine, we tested whether injection of
anti-FcεR1 antibody increases blood levels of IL-4 and
histamine. As seen in Fig. 2C, mice that were injected the
previous day with anti-FcεR1 had significantly higher
frequencies of circulating IL-4, as measured by in vivo
cytokine capture assay, compared to isotype antibody
treated controls (p=0.0015, median 863 pg/ml, range
0–1173 pg/ml vs. 10 pg/ml, range 0–34 pg/ml). Similarly,
histamine, which was measured in peripheral blood obtained
30 min after antibody injection due to its very short half-life,
was substantially higher in anti-FcεR1-treated mice than in
controls. Mice that received anti-FcεR1 had a median blood
histamine concentration of 28,800 nmol (range
7745–137,700 nmol) as compared to only 248 nmol (range
81–441 nmol, pb0.0001, Fig. 2D). As basophils and mast cells
are the only cells that contain pre-formed histamine, these
results demonstrate that anti-FcεR1 antibody injection
activates basophils and mast cells in vivo.
3.3. Anti-FcεR1 treatment delays diabetes onset in
NOD mice
To test the hypothesis that chronic activation of basophils
and mast cells protects against autoimmune diseases,
development of Type 1 diabetes was monitored in NOD
mice that were given weekly anti-FcεR1 antibody injections
from 6 weeks of age.
Repeated injections with anti-FcεR1 significantly reduced
blood glucose concentrations in NOD mice at 20 and 24–
28 weeks of age compared to control animals (Fig. 3A) and
delayed the onset of diabetes (onset of diabetes in 50% of the
animals: IgG group: 20 weeks of age, anti-FcεR1: 30 weeks of
age, Fig. 3B). Histological analysis of the pancreas revealed
that anti-FcεR1-treated mice had an increased total number
of β-islet cells and less lymphocyte infiltration of the
pancreatic islets compared to IgG treated mice at 16-
weeks of age, although these differences were not statisti-
cally significant (Fig. 3C).
Shorter anti-FcεR1 antibody treatment periods from 6 to
9 weeks of age did not provide a similar protective effect.
Neither 4 weekly injections with 50 μg of anti-FcεR1
antibody, nor 4 weeks of injections with 25 or 50 μg twice
a week decreased blood glucose levels or the frequency of
diabetic NOD mice compared to isotype antibody-treated
controls (Figs. 3D,E).
3.4. Anti-FcεR1 treatment induces a Th2 shift in
antibody, but not cytokine production
The effect 10 weeks of anti-FcεR1 treatment has on cellular
cytokine production was evaluated from spleen and pancre-
atic lymph node cells of 16 week old NOD mice after
stimulation with anti-CD3/anti-CD28. IFNγ and IL-4 levels
were similar between isotype antibody-injected controls and
anti-FcεR1-treated animals (Figs. 4A,B), whereas the con-
centration of IL-5 was significantly increased in anti-FcεR1-
treated mice (Fig. 4C). Pancreatic lymph node cells from
anti-FcεR1-injected mice produced more IL-5 and IFNγ, in
response to anti-CD3/anti-CD28 compared to controls,
although these differences did not reach statistical signifi-
cance (Figs. 4D,E).
Frequencies of splenic CD4+IFNγ+ T cells and CD8+IFNγ+
T-cells (Figs. 4F,G) as well as CD4+IL-4+ T-cells (Fig. 4H) after
in vitro stimulation with anti-CD3/anti-CD28 were not
significantly affected by anti-FcεR1 treatment. Frequencies
of splenic anti-CD3/anti-CD28 stimulated CD4+IL-17+ T-cells
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were increased in anti-FcεR1-treated animals compared to
controls, though this difference did not reach statistical
significance (p=0.079, Fig. 4I).
As antigen-specific cellular immune responses are diffi-
cult to detect in NOD mice, we tested whether repeated
anti-FcεR1 antibody injections induce either insulin-specific
Th1 (IgG2c) or Th2 (IgG1) associated antibody subsets. Mice
that were treated for 10 weeks with anti-FcεR1 antibodies
had significantly increased levels of insulin-specific IgG1
compared to isotype antibody-injected controls whereas
levels of insulin-specific IgG2c were unchanged (Figs. 4J,K).
3.5. Anti-FcεR1 treatment induces a marginal
increase in regulatory responses
Frequencies of regulatory T andB cells and theproduction of the
immunoregulatory cytokine IL-10 were measured from spleen
and pancreatic lymph node cells in response to anti-CD3/anti-
CD28 after 10 weeks of anti-FcεR1 antibody treatment to assess
the development of a regulatory immune response.
While repeated anti-FcεR1 antibody treatment did not
substantially alter the percentage of CD4+ T-cells that were
CD25+FoxP3+ in the spleen (mean 12.5% in isotype treated
mice vs. 13.3% in anti-FcεR1-treated, Fig. 5A), mean percent-
ages of CD4+CD25+FoxP3+ regulatory T cells in the pancreatic
lymph nodes did increase substantially (3% in isotype-treated
vs. 5.2% in anti-FcεR1-treated, Fig. 5B) though this difference
did not reach statistical significance (p=0.17).
Similarly, percentages of CD8+ spleen cells that were
positive for FoxP3+ (Fig. 5C), splenic B-cells that produced
IL-10 (Fig. 5D), and splenic B-cells that expressed a
regulatory phenotype (B220+CD1d+CD5+, Fig. 5E) were all
increased after anti-FcεR1-treatment, though none reached
statistical significance.
Repeated anti-FcεR1 antibody injections also slightly
increased splenic (p=0.18, Fig. 5F) and pancreatic lymph
node cell (p=0.44, Fig. 5G) IL-10 production in response to
anti-CD3/anti-CD28, though again the increases were not
statistically significant.
3.6. Histamine signaling through H1 and H2
receptors is not necessary for anti-FcεR1 induced
delay of Type 1 diabetes
As injection with anti-FcεR1 resulted in the release of
increased amounts of histamine and as histamine can have
immunomodulatory properties, we tested whether blockade
of H1 and H2 histamine receptors would prevent anti-FcεR1-
mediated delay of diabetes onset in NOD mice.
Cimetidine (an H2 receptor blocker) and fexofenadine (an
H1 receptor blocker) were administered by addition to the
drinking water of NOD mice from 6 weeks of age to study
endpoint at 25 weeks of age at concentrations used by prior
investigators [28,29].
Efficacy of H2-receptor blockade was confirmed by a
significant increase in the stomach pH of treated animals
compared to controls (Fig. 6A). Blockade of H1-receptors was
confirmed by evaluating changes in vascular leak in response
to intradermal anti-FcεR1 injection. To improve visualization
of vascular leakage in the ear, NOD mice were given
intravenous injections of toluidine blue. Control NOD mice
exhibited substantial local vascular leakage in response to
intradermal injection with anti-FcεR1 antibody whereas
fexofenadine-treated mice did not (Fig. 6B, left ears).
Vascular leakage was a specific response to anti-FcεR1
antibody, as intradermal injection of control antibody did
not induce vascular leakage (Fig. 6B, right ears).
As seen in Figs. 6C and D, continuous histamine receptor
blockade did not negate the protective effect of anti-FcεR1
antibody treatment on the development of diabetes in NOD
mice. Anti-FcεR1 antibody treatment during histamine
receptor blockade resulted in significantly reduced blood
glucose levels at 17–21 weeks of age (Fig. 6C) and delayed
the onset of diabetes compared to control animals (onset of
diabetes in 50% of the animals: IgG isotype group: 17 weeks of
age, anti-FcεR1 antibody group: 23 weeks of age, Fig. 6D).
3.7. Efficacy of anti-FcεR1 antibody-mediated
protection is reduced in the absence of IL-4
As anti-FcεR1 antibody injection increased in vivo IL-4 levels and
as IL-4 can counterbalance pathogenic Th1 autoimmune re-
sponses, we tested whether the protective effect of anti-FcεR1
antibody was dependent on IL-4 by treating IL-4-deficient NOD
mice with repeated weekly anti-FcεR1 injections.
Weekly injections of anti-FcεR1 or control IgG were given
from 6 to 20 weeks of age. Although blood glucose levels were
reduced in anti-FcεR1-treated IL-4-deficient animals (Fig. 7A)
the difference compared to IgG treated animals was less
prominent than had been previously observed in immunocom-
petent NOD mice (Fig. 3A) and did not reach statistical
significance. Similarly, protection against overt diabetes,
while still present (onset of diabetes in 50% of the animals:
isotype antibody group: 24 weeks of age, anti-FcεR1 antibody
group: 26 weeks of age, Fig. 7B), was substantially less than
had been observed in immunocompetent mice (Fig. 3B).
4. Discussion
This study demonstrates that repeated anti-FcεR1 therapy
protects against Type 1 diabetes in the NOD mouse model.
Continuous administration of anti-FcεR1 antibody reduced
the incidence of diabetes in NOD mice by ~50% compared to
controls and was associated with increased total numbers of
pancreatic β-islet cells. The protective effects appeared
dependent on chronic treatment with anti-FcεR1 antibody,
as shorter treatment regimens for 4 weeks did not result in
appreciable disease protection. Future studies will optimize
anti-FcεR1 antibody concentrations and administration in-
tervals to further improve protection.
In vitro and in vivo assays showed that anti-FcεR1 antibody
activates basophils and mast cells and greatly increases
circulating levels of histamine and IL-4. This result was not
unexpected, as basophils and mast cells both release
histamine and IL-4 in response to FcεR1-mediated signaling.
We suspect that the bulk of the IL-4 release was due to
basophil activation, since basophils are the only cells known
to store large quantities of pre-formed IL-4 [30], are major
contributors of IL-4 in helminth infections and allergic
diseases [17,18,31], and have been demonstrated to release
more IL-4 on a per cell basis than other cell types [32,33]. To
our knowledge this is the first demonstration that chronic
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activation of basophils and mast cells is associated with
protection against autoimmunity.
Although continuous treatment with anti-FcεR1 antibody did
not result in a clear Th2 shift in cytokine production, as
measured from spleen and pancreatic lymph node cells,
increases in insulin-specific IgG1 revealed a type 2 immune
shift in antibody production. Increased serum levels of IL-4
following anti-FcεR1 antibody treatment suggest that this type 2
immune shift in antibody responsesmayhavebeendrivenby IL-4
released from innate cells activated by antibody rather than
T-cells. This type 2 immune shift in insulin-specific antibody
isotypes is similar to that observed when NODmice are infected
with the filarial nematode Litomosoides sigmodontis [8], an
intervention that also results in protection against diabetes.
While histamine signaling through H1 and H2 receptors does
not appear necessary for protection, as treatment with H1 and
H2 receptor blockers did not attenuate the protective effects
of anti-FcεR1 injections, results obtained with IL-4 deficient
NOD mice demonstrate that IL-4 is partly responsible for the
therapeutic benefit. The finding that IL-4 protects against
autoimmune disease is consistent with prior studies. In NOD
mice systemic administration of IL-4 [34,35], expression of IL-4
by pancreatic β-islet cells [36], and transfer of IL-4 expressing
DCs [37,38] have been shown to prevent the onset of
autoimmune diabetes. An important role for IL-4 in the control
of Th1-driven autoimmune diseases is further suggested by
studies that used helminths to prevent autoimmunity.
Helminth or helminth antigen induced protection against
autoimmune diabetes is associated with the induction of Th2
immune responses [8] and studies in experimental autoim-
mune encephalitis and trinitrobenzene sulfonic acid (TNBS)
induced colitis showed that Schistosoma egg administration
failed to protect against autoimmunity in mice deficient in
STAT6 or depleted of IL-4 [39].
Besides counterbalancing Th1 immune responses, FcεR1-
induced IL-4 may protect against Th1 driven autoimmune
responses by driving the differentiation of classically
activated (Th1 associated) macrophages into an alternative
activated phenotype (AAMØ). AAMØ are anti-inflammatory
and are known to be more prevalent during helminth
infections [40]. Future studies will investigate whether
FcεR1-treatment induces AAMØ and whether this cell
population contributes to the protective effect.
The novelty of this study is that we were able to induce
IL-4 release by systemically activating basophils and mast
cells with an antibody that directly cross-links FcεR1s. An
approach that is based on antibody injections to trigger IL-4
release might be easier to transfer to the bedside compared
to therapies that consist of injection with cytokines.
Additionally, given that the protective effects of anti-FcεR1
therapy were only partially reduced in IL-4-deficient NODmice,
it is likely that IL-4 independentmechanismsmayalso play a role
in anti-FcεR1 therapy. These may be directly related to
activation of basophils and/or mast cells, or they may be due
to induction of negative feedback pathways induced by chronic
activation of these cells. Determining the protective mecha-
nisms of repeated anti-FcεR1 injections that are IL-4 indepen-
dent will be a focus of studies in the future.
One IL-4-independent mechanism may be the induction of
IL-13 release by anti-FcεR1 injections as IL-13 has been
shown to prevent diabetes onset in NOD mice [41]. Both
basophils and mast cells can produce IL-13 after cross linking
of FcεR1. Because IL-13 signals through IL-4Rα it is possible
that anti-FcεR1-induced IL-13 assumed some of the functions
of IL-4 in IL-4 deficient NOD mice and contributed to anti-
FcεR1 mediated protection. Evaluating whether IL-13 plays a
role in anti-FcεR1 mediated protection against autoimmunity
will be the subject of future studies.
In contrast, the observed non-significant increase of Th17
cells during anti-FcεR1 therapy is very unlikely to be a
mechanism by which anti-FcεR1 injections protect against
Type 1 diabetes since Th17 responses are thought to have a
role in the induction of Type 1 diabetes, possibly by conversion
of Th17 to Th1 cells that can cause diabetes onset [42–45].
Another IL-4-independent mechanism that may be impor-
tant is the induction of immunoregulatory networks. By
repeatedly activating basophils and mast cells, we replicated
the immunological phenotype observed in chronic helminth
infections and in allergen immunotherapy. In helminth in-
fections, basophils and mast cells are continuously being
activated by parasite antigens through parasite-specific IgE on
the surface of these cells [16]. In immunotherapy, patients
with allergen-specific IgE are repeatedly given injections of
allergen to which they have specific IgE, essentially inducing a
chronic state of low level basophil and mast cell activation.
While the mechanisms by which chronic helminth infections
and allergen immunotherapymodulate the immune systemare
not completely understood, a number of studies show that
both augment key regulators of peripheral tolerance such as
IL-10 and T-regulatory cells. Indeed, helminth infections
shown to protect against autoimmune diseases in animal
models have been repeatedly associated with increases of
IL-10 and T-regulatory cells [8,46,47].
In our study, while not statistically significant, levels of
IL-10 production from splenocytes, frequencies of IL-10 pro-
ducing B cells, and frequencies of regulatory CD4+FoxP3+
T-cells, CD8+FoxP3+ T-cells, and CD1d+CD5+ B-cells were
all higher in mice receiving anti-FcεR1 antibody injections.
As one of the hallmarks of autoimmune diseases is the loss
of peripheral tolerance [48], it will be important for future
studies to more fully evaluate whether anti-FcεR1 therapy
functions by augmenting peripheral tolerance. In a similar
vein, it would be interesting to evaluate whether allergen
immunotherapy in allergic patients has had beneficial
effects on patients with concurrent autoimmune diseases.
Future studies will also attempt to further define exactly
which cells are involved in anti-FcεR1-mediated protection.
In particular, it will be important to determine whether
basophils and/or mast cells are necessary for the protective
effects of anti-FcεR1 therapy. We have shown that anti-
FcεR1 therapy activates these cells, but have not yet
demonstrated that these cells are essential. As there are
currently no basophil-deficient nor mast-cell deficient mice
on a NOD background, it will be necessary to develop
techniques of depleting basophils and mast cells without
concurrently activating them. Additionally, it has recently
been shown that antigen-presenting DCs can express FcεR1 in
the setting of Th2 inflammation and be depleted by anti-
FcεR1 treatment [49]. While it is unlikely these cells play a
role in the Th1-mediated pathology of Type 1 diabetes,
future studies will also evaluate whether FcεR1+ DCs play a
role in FcεR1-mediated protection against Type 1 diabetes.
Clinically, it is important to ask whether induction of
chronic basophil and mast cell activation could actually be
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used to protect against autoimmune diseases. While at first
blush such an approach sounds preposterous given the
obvious risk of anaphylaxis, we believe that chronic basophil
and mast cell activation could be a safe and feasible therapy.
We propose that the key to safety would be to start
treatment with small amounts of anti-FcεR1 antibody, or
another basophil/mast cell activating agent, followed by a
gradual increase in treatment dosage. Repeated administra-
tion of gradual increasing amounts of anti-FcεR1 did not
cause anaphylaxis in the mice we studied, and such an
approach would be similar to allergen immunotherapy, in
which the dose of allergen given is gradually increased over
time. Allergen immunotherapy induces repeated basophil
and mast cell activation and is routinely conducted in the
outpatient arena for diseases as benign as allergic rhinitis.
Importantly, unlike conventional therapies for autoimmune
diseases which predominantly work by incapacitating specific
arms of the immune system, a therapeutic approach based on
the induction of chronic basophil and mast cell activation has
the potential to induce a therapeutic effect without irreversibly
inhibiting any pathways of the immune system.
In conclusion, this study demonstrates that repeated
administration of anti-FcεR1 antibodies results in activation of
basophils andmast cells and protection against Type 1 diabetes
in NODmice by amechanism that is partially dependent on IL-4.
While IL-4 has been previously shown to protect against Th1-
driven autoimmune diseases, the utilization of repeated
antibody injections to induce IL-4 release represents a novel
approach for the treatment of autoimmune diseases. Given the
feasibility of developing antibodies for use in humans, such an
approach has the potential to be translated into a novel clinical
therapy for Th1-driven autoimmune diseases. In addition to
evaluating the safety and feasibility of this approach as a
therapy for humans with autoimmune diseases, future studies
will also focus on obtaining a better understanding of how
helminth infections protect against autoimmune diseases to
enable development of other novel therapeutic strategies.
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